JP2021522864A - Ｂ型肝炎感染症を処置するための方法および組成物 - Google Patents

Ｂ型肝炎感染症を処置するための方法および組成物 Download PDF

Info

Publication number
JP2021522864A
JP2021522864A JP2021513373A JP2021513373A JP2021522864A JP 2021522864 A JP2021522864 A JP 2021522864A JP 2021513373 A JP2021513373 A JP 2021513373A JP 2021513373 A JP2021513373 A JP 2021513373A JP 2021522864 A JP2021522864 A JP 2021522864A
Authority
JP
Japan
Prior art keywords
loop
antigen epitope
epitope repeat
hbsag
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021513373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522864A5 (https=
Inventor
ルネ ウォルシュ
ルネ ウォルシュ
ステファン ロサルニニ
ステファン ロサルニニ
ハンス ネッター
ハンス ネッター
ロナルド ファーカー
ロナルド ファーカー
Original Assignee
クリアビー セラピューティクス リミテッド
クリアビー セラピューティクス リミテッド
メルボルン ヘルス
メルボルン ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリアビー セラピューティクス リミテッド, クリアビー セラピューティクス リミテッド, メルボルン ヘルス, メルボルン ヘルス filed Critical クリアビー セラピューティクス リミテッド
Publication of JP2021522864A publication Critical patent/JP2021522864A/ja
Publication of JP2021522864A5 publication Critical patent/JP2021522864A5/ja
Priority to JP2024066590A priority Critical patent/JP2024105291A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021513373A 2018-05-10 2019-05-09 Ｂ型肝炎感染症を処置するための方法および組成物 Pending JP2021522864A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024066590A JP2024105291A (ja) 2018-05-10 2024-04-17 Ｂ型肝炎感染症を処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669663P 2018-05-10 2018-05-10
US62/669,663 2018-05-10
PCT/US2019/031483 WO2019217654A1 (en) 2018-05-10 2019-05-09 Methods and compositions for the treatment of hepatitis b infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024066590A Division JP2024105291A (ja) 2018-05-10 2024-04-17 Ｂ型肝炎感染症を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021522864A true JP2021522864A (ja) 2021-09-02
JP2021522864A5 JP2021522864A5 (https=) 2022-05-10

Family

ID=68466904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513373A Pending JP2021522864A (ja) 2018-05-10 2019-05-09 Ｂ型肝炎感染症を処置するための方法および組成物
JP2024066590A Pending JP2024105291A (ja) 2018-05-10 2024-04-17 Ｂ型肝炎感染症を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024066590A Pending JP2024105291A (ja) 2018-05-10 2024-04-17 Ｂ型肝炎感染症を処置するための方法および組成物

Country Status (10)

Country Link
US (4) US11773141B2 (https=)
EP (2) EP3810625B1 (https=)
JP (2) JP2021522864A (https=)
KR (2) KR20250027279A (https=)
CN (3) CN120571006A (https=)
AU (2) AU2019267680C1 (https=)
CA (1) CA3099726A1 (https=)
ES (1) ES2985391T3 (https=)
PL (1) PL3810625T3 (https=)
WO (1) WO2019217654A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244940A1 (en) * 2024-05-21 2025-11-27 Clearb Therapeutics Ltd. Methods and compositions for mrna- and dna-based treatment of hepatitis b infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504067A (ja) * 2000-07-31 2004-02-12 ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス 改良されたウイルス様粒子
US20060246089A1 (en) * 2002-09-18 2006-11-02 Yuzhang Wu Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP2292642A1 (en) 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
AU2015259470A1 (en) * 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504067A (ja) * 2000-07-31 2004-02-12 ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス 改良されたウイルス様粒子
US20060246089A1 (en) * 2002-09-18 2006-11-02 Yuzhang Wu Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol. 10, Issue 2, e0118062, JPN7023001310, 2015, ISSN: 0005423175 *

Also Published As

Publication number Publication date
AU2019267680C1 (en) 2025-02-27
EP3810625A1 (en) 2021-04-28
JP2024105291A (ja) 2024-08-06
CN119113097A (zh) 2024-12-13
ES2985391T3 (es) 2024-11-05
AU2019267680B2 (en) 2024-07-25
KR20250027279A (ko) 2025-02-25
AU2019267680A1 (en) 2020-11-26
EP3810625B1 (en) 2024-05-22
EP3810625A4 (en) 2022-05-11
WO2019217654A1 (en) 2019-11-14
US12202862B2 (en) 2025-01-21
US11773141B2 (en) 2023-10-03
US20250333450A1 (en) 2025-10-30
KR20210010872A (ko) 2021-01-28
EP4389222A2 (en) 2024-06-26
CN112513063A (zh) 2021-03-16
EP4389222A3 (en) 2024-08-28
CA3099726A1 (en) 2019-11-14
CN120571006A (zh) 2025-09-02
US20220002349A1 (en) 2022-01-06
US20250145669A1 (en) 2025-05-08
AU2024227453A1 (en) 2024-11-21
US20240150412A1 (en) 2024-05-09
PL3810625T3 (pl) 2025-03-03

Similar Documents

Publication Publication Date Title
EP2858674B1 (en) An antibody composition for prevention or treatment of mutant hepatitis b virus infection
Menne et al. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection
US20250333450A1 (en) Methods and compositions for the treatment of hepatitis b infection
Wang et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
CN120888568A (zh) 一种预防或治疗乙肝病毒感染的mRNA疫苗及其应用
HK40106023A (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491B (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491A (en) Methods and compositions for the treatment of hepatitis b infection
TW202547530A (zh) 用於基於ｍＲＮＡ及ＤＮＡ之Ｂ型肝炎感染治療的方法及組合物
Ifeanyi A Review on Hepatitis B Virus and Hepatocellular Carcinoma
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
CN104474548B (zh) 预防和/或治疗慢性病毒感染的产品及方法
Mancini-Bourgine et al. Impact of the immunogen nature on the immune response against the major HBV antigens in an HBsAg and HLA-humanized transgenic mouse model
US20230079898A1 (en) Compositions and methods for treating and preventing hepatitis b and d
WO2016114676A1 (en) An immunogenic vaccine against the hcv and/or hbv
GB2440528A (en) Antigen-antibody complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240620

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240829

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240927